Unten finden Sie die vollständige Liste unserer Pressemitteilungen (Seite 22 von 28):
FDA converts selpercatinib to traditional approval for RET-mutant medullary thyroid cancer. LIBRETTO-531 trial data met confirmatory evidence requirements under accelerated approval pathway.
Parexel acquires Vitrana to expand AI-powered pharmacovigilance. QA and regulatory affairs teams face new audit and compliance considerations for outsourced safety reporting.
Cristcot names Rayna Herman President of its hydrocortisone acetate commercial division as the company's ngHCA suppository awaits FDA review. Full analysis.
Kyowa Kirin secures public reimbursement for burosumab across four Canadian provinces and the federal NIHB program, closing a coverage gap for adults with XLH.
Crinetics secures EC approval for the first once-daily oral acromegaly treatment in the EU, launching in Germany and Austria with broader access plans.
Johnson & Johnson exits CD20 and CD19-CD20 CAR-T programs for large B-cell lymphoma. Key implications for CDMOs, cell therapy manufacturing, and regulatory affairs leads.
Tarsus Pharmaceuticals starts Phase 2 Calliope trial for TP-05 Lyme disease prevention. Topline data expected H1 2027. XDEMVY Q1 sales up 85% YoY.
Ascendis Pharma's ApproaCH Trial delivers two-year navepegritide data with sustained AGV gains and clean safety record, advancing NDA positioning in achondroplasia.
FDA accepts Mineralys Therapeutics NDA for lorundrostat with a December 22, 2026 PDUFA date. Key CMC, process validation, and pre-approval manufacturing implications.
CARBOGEN AMCIS Shanghai facility passes an unannounced NMPA GMP inspection, reinforcing compliance standards for contract manufacturers in China.
Parexel acquires Vitrana to integrate AI-driven pharmacovigilance. QA and regulatory leads must assess change control and re-validation obligations under 21 CFR Part 314.
Angelini Pharma's $4.1B acquisition of Catalyst Pharmaceuticals brings three FDA-approved rare disease assets and U.S. GMP supply chains under Italian ownership.
Catalyst Pharmaceuticals resolves all FIRDAPSE ANDA patent challenges. Hetero Labs barred from generic entry before January 2035. Full settlement details inside.
Zealand Pharma and Roche advance petrelintide to Phase 3 in H2 2026 after positive ZUPREME-1 data. Key CMC and process validation implications for manufacturing teams.
Roche acquires PathAI for $750M upfront to integrate AI pathology tools into companion diagnostics. Closing expected H2 2026. Key implications for biopharma manufacturers.
Neuland Labs and LIR Life partner on a patch-based transdermal GLP-1 obesity therapy platform. Key implications for API sourcing, QA, and process validation teams.
Safic-Alcan acquires majority stake in SA Ingredients, reshaping pharma excipient distribution in India. QA and supply chain implications for GMP manufacturers.
Bayer's $2.45B acquisition of Perfuse Therapeutics transfers Phase II ocular asset PER-001 into its GMP infrastructure. Key implications for CDMOs and regulatory teams.
3PBIOVIAN integrates isolator-based sterility testing across its Spanish and Finnish CDMO sites, targeting faster batch release and stronger sterility assurance for biopharma clients.
Ascendis Pharma's YUVIWEL gains FDA accelerated approval for achondroplasia. Q1 2026 results show €197M YORVIPATH revenue and a $187.5M PRV sale.
Insmed's MHRA authorisation for BRINSUPRI and pending Japan decision create multi-market GMP supply chain demands. Q1 2026 revenues hit $306M. Full analysis.
Lexicon Pharmaceuticals targets mid-2026 ZYNQUISTA NDA resubmission for T1D, contingent on STENO1 meeting FDA patient exposure and safety data requirements.
NewAmsterdam Pharma expects EMA, MHRA, and Swissmedic decisions on obicetrapib in H2 2026. Menarini targets Q4 launches in Germany and UK. PREVAIL interim analysis due Q4 2026.
Aclaris ATI-052 Phase 1a data confirm 45-day half-life and quarterly dosing potential. Key implications for biologics manufacturing and fill-finish planning ahead of Q4 2026 Phase 2b start.
FDA tentatively approves Lantheus's PNT2003 as the first radioequivalent for Lu 177 Dotatate, setting a GMP and regulatory benchmark for radiopharmaceutical generics.
Plus Therapeutics' CNSide Diagnostics secures Medicare PTAN from CMS. CLFS pricing for CPT 0640U targeted July 2026, pending MAC coverage determinations.
FDA accepts single-arm historical control design for tab-cel EBV+ PTLD resubmission. Key implications for cell therapy CMC and regulatory affairs teams.
Cadrenal Therapeutics receives FDA EOP2 minutes for CAD-1005 in HIT, setting a 120-patient Phase 3 trial and 2029 NDA target. CMC implications for sponsors.
FDA's CDER and Critical Path Institute launch a one-year lysosomal diseases pre-consortium to shape drug development standards and regulatory pathways for rare disease sponsors.
CDT Equity notes Sarborg's agentic AI-generated substance of matter patent in cystic fibrosis, filed in under three weeks. Key implications for rare disease IP strategy.
Filana Therapeutics is submitting preclinical data and protocol modifications to lift an FDA Clinical Hold on simufilam for TSC-related epilepsy. Q1 2026 financials inside.
Novartis breaks ground on a 46,000 sq. ft. radioligand therapy site in Denton, Texas. Fifth US RLT facility targets 2028 operations within a $23B investment plan.
CARsgen's satri-cel targets NMPA approval as the world's first CAR-T therapy for gastric cancer, setting ATMP manufacturing and regulatory benchmarks globally.
Merck closes $5.8B Terns Pharma acquisition. TERN-701's FDA Breakthrough Therapy Designation accelerates CMC planning and manufacturing integration timelines.
Oragenics signs LOI to license Sigyn's CardioDialysis™ for TBI, combining it with Phase IIa ONP-002 in a dual-modality inflammation strategy with no approved rivals.
EMA finalises 2026/2027 seasonal flu vaccine strain recommendations with trivalent shift and platform-specific differences. Variation submissions due 15 June 2026.
FDA CDER and CBER issue technical specifications for CGM data submission in clinical trials supporting NDA and BLA applications. Key details for regulatory teams.
Eli Lilly commits $4.5B to expand Lebanon, Indiana API and Advanced Therapies sites. Key implications for QA, regulatory affairs, and domestic manufacturing strategy.
Dr. Reddy's and Nestlé Health Science launch Celevida GLP+ in India to address protein deficiency in GLP-1 therapy patients. Regulatory and market implications explained.
Neurobion enters the topical analgesic segment with a 0.075% capsaicin nerve pain cream, raising GMP and regulatory considerations for manufacturers.
LeonaBio adds Fred Callori, Natalie Holles, and Peter Silverman to its board, reinforcing governance ahead of oncology and neurology pipeline advancement.
DKMS Foundation India offers free HLA typing for children under 12 with transfusion-dependent thalassaemia, addressing a key pre-transplant diagnostic barrier in India.
Practo's AI-driven healthcare marketplace surpasses $100M GMV, handling 20,000+ daily interactions. Key compliance and vendor qualification implications for health system operators.
FDA grants accelerated approval to Rocket Pharmaceuticals' Kresladi for pediatric LAD-I. CBER cites CMC flexibility, key signal for rare disease gene therapy submissions.
Angelini Pharma's acquisition of Catalyst Pharmaceuticals raises rare disease supply continuity and regulatory integration questions for QA and regulatory leads.
FDA CDER's LEADER 3D initiative offers regulatory affairs teams structured guidance on rare disease trial design, endpoint selection, and orphan drug submission strategy.
Roche acquires PathAI for up to $1.05B, reshaping companion diagnostics and QA workflows for pharma manufacturers in precision medicine programmes.
WHO confirms hantavirus cases on MV Hondius cruise ship, with 3 deaths and contact tracing spanning Europe and Africa.
Three passengers die from hantavirus on cruise ship MV Hondius, including a Dutch couple and German national, as contact tracing spans globally.
Hantavirus symptoms from MV Hondius cruise can escalate from mild flu to severe lung failure. Authorities urge early medical attention globally.
Spain's Canary Islands blocked MV Hondius over hantavirus fears before WHO pressure forced a reversal, allowing the ship to dock in Tenerife.
Scientists explain why the Andes hantavirus strain is unique among known strains but poses no COVID-like pandemic risk despite MV Hondius outbreak.
Biogen's 28-mg nusinersen gained FDA approval March 30, 2026. A 50-mg loading dose requires separate payer authorization. Key implications for access and formulary teams.
Plus Therapeutics' REYOBIQ shows 9-month median OS in leptomeningeal metastases Phase 1. Key manufacturing and regulatory implications for CNS radiopharmaceuticals.
MilliporeSigma secures exclusive 5-year testing deal with Genetix Biotherapeutics for gene therapies targeting sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Cirena licenses Agilent RNA purification technology to solve purity challenges in long RNA manufacturing for genome editing, implications for CMOs and QA teams.
WHO alerts 12 countries as Andes hantavirus kills three and infects eight aboard cruise ship MV Hondius, with global contact tracing underway.
Canary Islands blocked MV Hondius docking over hantavirus fears before WHO cited Spain's legal obligation, with disembarkation set for May 11.
The Andes hantavirus behind the MV Hondius outbreak is the only strain known to spread between humans, with no antiviral treatment available.
29 MV Hondius passengers left before hantavirus was confirmed, triggering contact tracing across 12 countries with a KLM crew member now symptomatic.
Sanofi India partners with NHM Madhya Pradesh to expand NCD awareness, rare disease screening, and mobile medical unit deployment across the state.
Full timeline of the MV Hondius hantavirus outbreak, from the first death on April 11 to WHO intervention and Canary Islands disembarkation on May 11.
FDA updates the Biomarker Qualification Program Letter of Intent outline and pre-LOI meeting process under the 21st Century Cures Act DDT qualification pathway.
FDA's final postapproval pregnancy safety study guidance sets design standards for sponsors under CDER and CBER. Key implications for regulatory affairs teams.
FDA finalizes Clostridioides difficile infection drug development guidance (FDA-2022-D-1261), covering treatment, recurrence reduction, and prevention pathways for sponsors.
FDA CDER finalizes pulmonary tuberculosis drug development guidance under docket FDA-2013-D-1319. Key clinical trial considerations for antibacterial sponsors.
FDA's final guidance on postapproval pregnancy safety studies sets methodology standards for registries, real-world data, and case reports. Key read for regulatory and PV teams.
Moleculin Biotech adds Hong Kong to its liposomal Annamycin IP portfolio ahead of Phase 3 AML data, with exclusivity running through 2040.
FDA's seventh CNPV pilot approval covers Bizengri (zenocutuzumab-zbco) for NRG1 fusion-positive cholangiocarcinoma. Key implications for regulatory and QA teams on accelerated approval timelines.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma five months early under the CNPV pilot, reshaping rare oncology manufacturing timelines.
Pharma AI & Data Congress 2026 launches June 3 in Mumbai for 130+ pharma IT leaders to tackle AI deployment under GAMP AI, EU AI Act, and DPDPA compliance.
CARBOGEN AMCIS Shanghai cleared an unannounced NMPA GMP audit on 14 April 2026 with zero deficiencies. Key implications for CDMO qualification and API supply.
Bristol Myers Squibb secures EMA approval for Sotyktu as the first TYK2 inhibitor for psoriatic arthritis. Key implications for EU GMP, API sourcing, and batch scale-up.
FUJIFILM Biosciences and NextCell launch a platform targeting MSC variability and GMP workflow gaps in ATMP manufacturing as regulatory scrutiny intensifies.
Biocon Pharma secures Health Canada approval for Micafungin for Injection USP 50 mg and 100 mg, advancing its sterile injectable generics footprint in Canada.
Symeres names Henning Steinhagen CEO with 25+ years across pharma, biotech and CDMO sectors, signalling a push for global expansion and broader service capabilities.
Robocath closes first-in-human enrollment for its robotic PCI platform in France, advancing toward EU MDR regulatory submission. Key details for device and regulatory leads.
Abbott's TriClip launch in India introduces catheter-based tricuspid valve repair, raising device governance, procurement, and CDSCO compliance obligations for cardiac centers.
Miror Therapeutics, BESCOM, and Soham Foundation launch a menopause and HRT awareness programme for women employees at BESCOM's Bengaluru headquarters.
Abeona Therapeutics adds CHOP as its sixth ZEVASKYN Qualified Treatment Center, raising GMP handling and chain-of-identity demands across the autologous gene therapy network.
FibroBiologics advances its fibroblast cell therapy into Hantavirus pulmonary syndrome, leveraging ARDS preclinical data where no approved treatments exist.
Reunion Neuroscience secures FDA Breakthrough Therapy Designation for luvesilocin in PPD. Phase 3 targets 2026 with subcutaneous GMP and DEA compliance challenges ahead.
FDA's public docket on drug repurposing targets labeling modernization for approved assets in metabolic, rare, and neurodegenerative disease. Key read for regulatory affairs teams.
Ipsen voluntarily withdraws Tazverik after SYMPHONY-1 trial records 5.7% hematologic SPM rate. Key implications for QA and regulatory affairs teams on accelerated approval accountability.
Cellectis sets a 2028 BLA target for allogeneic CAR-T lasme-cel, with pivotal Phase 2 interim data due Q4 2026. CMC readiness now on the critical path.
Biomea Fusion completes chronic tox studies for icovamenib, enabling extended clinical dosing. Key implications for IND amendments and CMC strategy in diabetes trials.
Tonix Pharmaceuticals reports 3,588 patients initiated on TONMYA in Q1 2026. GPO deal covers 35M lives. FDA Type C meeting for TNX-4800 set for Q3 2026.
Elicio Therapeutics targets a mid-2026 Phase 2 DFS readout for ELI-002 7P in KRAS-mutant PDAC before requesting an End-of-Phase 2 FDA meeting on Phase 3 design.
aTyr Pharma targets June 2026 IND submission for efzofitimod Phase 3 in pulmonary sarcoidosis after FDA Type C meeting confirms FVC as primary endpoint.
Novo Nordisk's STEP UP data show semaglutide 7.2 mg achieved 27.7% weight loss in early responders. Supply-chain and fill-finish implications examined for pharma ops teams.
Roche gains CE Mark for Elecsys pTau217 Alzheimer's blood test. Key implications for anti-amyloid biologic manufacturers, CDx quality systems, and supply planning.
Corona Remedies acquires Wokadine brand, entering India's Rs. 648 Cr Povidone Iodine market after 17.3% revenue growth in FY26. GMP and regulatory implications.
J.B. Pharma shareholders approve Torrent Pharma merger at 51:100 swap ratio. NCLT clearance triggers GMP site rationalisation and regulatory transfer obligations.
Unicycive's OLC NDA resubmission targets a June 29, 2026 PDUFA date after CMO manufacturing progress resolved CMC gaps. Key read for QA directors managing external manufacturing.
Achieve Life Sciences targets Q4 2026 NDA resubmission for cytisinicline after OAI classification at prior CMO site, naming Adare Pharma Solutions as new primary manufacturer.
Collegium Pharmaceutical closes $650M AZSTARYS acquisition from Corium Therapeutics. Six Orange Book patents through 2037 and a manufacturing milestone earnout shape integration priorities.
Xilio Therapeutics targets mid-2026 IND submission for XTX501 bispecific PD-1/masked IL-2. Key CMC and process validation implications for QA and regulatory teams.
Sionna Therapeutics completes Phase 2a enrollment for NBD1 stabilizer SION-719. Dual-combination Phase 1 also on track. Summer 2026 topline data expected for both programs.
Rigel Pharmaceuticals licenses VEPPANU from Arvinas and Pfizer, taking on CMC and manufacturing responsibility for the first FDA-approved oral PROTAC drug.
EU Parliament and Council agree on Critical Medicines Act. EMA's MSSG gains supply chain vulnerability assessment mandate across 200+ active substances.
Achieve Life Sciences hires three Ohtuvayre launch veterans as it prepares for FDA review of cytisinicline, backed by a $354M milestone-linked financing deal.
The 6th Edition Drug Safety Symposium 2026 – India Chapter, presented by Eminence Business Media in Mumbai, explores practical pharmacovigilance challenges beyond AI, featuring Alkem, Cipla, Glenmark, and Amgen leaders.
Recordati meets Phase 2 primary endpoint for pasireotide in post-bariatric hypoglycemia and schedules FDA meeting. Q1 2026 revenue up 4.9% to €713.4M.
Zentalis selects pivotal dose for azenosertib WEE1 inhibitor and initiates Phase 3 ASPENOVA trial, targeting FDA accelerated approval in Cyclin E1-positive PROC by 2026.
CDC confirms Andes virus on MV Hondius cruise ship, traces U.S. passengers, and says American public risk remains extremely low.
MV Hondius passengers evacuated in Tenerife as hantavirus cases rise; WHO oversees repatriation of 15+ nationalities.
Stanford's Dr Salinas says MV Hondius hantavirus won't cause a pandemic but warns of rising zoonotic disease risk globally.
MV Hondius hantavirus outbreak hits 11 cases across 7 nations; Andes strain tied to Argentine rodent contact sparks global tracing.
MV Hondius hantavirus hits 11 cases, 3 deaths; 18 Americans held at Nebraska and Emory as WHO confirms no wider outbreak risk.
FDA and CDISC complete preliminary testing of Dataset JSON as a potential XPT v5 replacement. No timeline set; current SDTM and SEND standards remain in force.
Cabaletta Bio's Cellares commercial supply deal and ASGCT comparability data set the manufacturing foundation for rese-cel's planned 2027 BLA submission.
Cognition Therapeutics secures a second donation to extend its zervimesine expanded access program in DLB as an FDA registrational meeting approaches in Q2 2026.
Cellectar Biosciences closes $140M financing to advance iopofosine I 131 through Phase 3 and FDA accelerated approval in Waldenström Macroglobulinemia.
Ipsen presents corabotase at SCALE 2026 as the first RNI class biologic. Key biologics manufacturing and regulatory pathway implications for QA and regulatory leads.
Karyopharm completes XPORT-EC-042 enrollment with mid-2026 topline data due. SENTRY myelofibrosis results head to ASCO. sNDA and scale-up implications for selinexor.
Suven Life Sciences reaches 76% enrollment in Phase 3 masupirdine trial for Alzheimer's agitation. Baseline data consistent with prior studies. CMC and regulatory implications examined.
Imviva Biotech reports 100% SRI-4 response in SLE patients with allogeneic CAR-T CTA313. Key GMP and batch consistency implications for cell therapy manufacturers.
FDA approves expanded CRYSVITA dosing for adult XLH patients. Kyowa Kirin's post-approval label update offers a regulatory reference for rare disease biologic teams.
Forward Therapeutics completes Phase 1 for oral TNF inhibitor FT2109. What CMOs and QA directors need to know about formulation and GMP implications.
Grace Sciences selects 1e15 vg pivotal dose for GS-100 AAV9 gene therapy after immune-mediated events halt highest cohort in NGLY1 Deficiency phase 1/2/3 trial.
Oryzon prepares FDA protocol resubmission for PORTICO-2 Phase III vafidemstat trial in BPD aggression, while iadademstat posts strong AML data ahead of EHA 2026.
Tarsus Pharmaceuticals partners with John Cena to raise diagnosis rates for Demodex blepharitis, affecting 25M Americans, spotlighting FDA-approved XDEMVY.
FDA's Project Orbis concurrent review framework is reshaping CMC documentation and submission strategies for oncology drug manufacturers across global jurisdictions.
Monopar Therapeutics plans a mid-2026 NDA submission for ALXN1840 in neurologic Wilson disease. Key implications for CMC and regulatory teams preparing rare disease NDA packages.
FDA's evolving 503A bulks list tightens API supplier qualification and CoA requirements for compounding facilities. Key compliance actions for QA and regulatory leads.
FDA's ARC Program funds Bayesian trial design and ADTKD biomarker research via BAA contracts, shaping future CDER review standards for rare disease submissions.
FDA's Compounding Quality CoE launches free self-guided GMP training covering aseptic technique, CAPA, sterility assurance, and 503B compliance for outsourcing facilities.
Artelo Biosciences targets Q4 2026 enrollment for ART26.12 multiple ascending dose Phase 1 study after positive SAD data. Cash position at $10.3M as of Q1 2026.
Eton Pharmaceuticals launches DESMODA after FDA approval, relaunches HEMANGEOL, and raises 2026 revenue guidance to $120M following 73% Q1 sales growth.
Nurix Therapeutics presents Phase 1 tablet formulation data for BTK degrader bexobrutideg in CSU, showing deep tissue BTK degradation in healthy volunteers at SID 2026.
Medicus Pharma's D-MNA microneedle array hits registrational-grade clearance in Phase 2 BCC study. FDA pathway discussions and Orphan Drug application follow.
Sutro Biopharma advances STRO-004, STRO-006, and STRO-227 toward 2026 clinical milestones, testing its cell-free ADC conjugation platform across DAR8 and DAR10 formats.
Fortress Biotech's Cyprium closed a $205M Priority Review Voucher sale after FDA approved ZYCUBO® for Menkes disease. Key implications for rare disease regulatory strategy.
Lupin's Nagpur facility secures USFDA approval for Famotidine Injection USP, a generic of Pepcid injection. Key GMP and regulatory implications for sterile injectables.
Malta Medicines Authority grants EU GMP certification to Indoco Remedies' Baddi plant after a January 2026 inspection. Key compliance implications for QA directors.
Alembic Pharma receives USFDA tentative approval for Darolutamide Tablets 300 mg. Market estimated at $3.155B. What plant heads and QA leads need to track next.
Cipla clears FDA's AB-rating threshold for generic Ventolin HFA pMDI, the first such approval in the U.S. respiratory generics market. FY26 revenue hits Rs. 28,163 crore.
Telangana's life sciences ecosystem reaches $145B valuation after Rs. 84,000 crore investment. Key GMP and regulatory implications for global CDMOs and API supply chains.
The Lancet renames PCOS to PMOS after a 14-year global process, reflecting true hormonal and metabolic dysfunction in 170 million women.
Moleculin's MIRACLE trial reaches 45-subject enrollment, triggering June 2026 interim unblinding. Blinded CRc rate holds at 40% in relapsed/refractory AML.
aTyr Pharma targets a June 2026 IND filing for an efzofitimod Phase 3 sarcoidosis study after FDA Type C feedback shaped FVC endpoint selection.
ACG case study shows how equipment intervention restored dissolution performance on a Fexofenadine MUPS tablet, protecting a 180-day first-to-file ANDA exclusivity window.
Telix Pharmaceuticals signs LOIs with EDAP TMS and Profound Medical to explore gallium-68 PSMA-PET imaging in ablative prostate cancer workflows outside current approved indications.
AstraZeneca's durvalumab delivers perioperative survival gains in muscle-invasive bladder cancer, raising manufacturing, QA, and regulatory implications for CMC teams.
Recludix Pharma's oral STAT6 inhibitor REX-8756 matched monoclonal antibody efficacy in atopic dermatitis preclinical models with a cleaner safety profile than JAK inhibitors.
FDA's active accelerated approval list flags VIMKUNYA and CAPVAXIVE with postmarketing trial deadlines through 2030. Key compliance dates for regulatory teams.
FDA withdrew Ixchiq's chikungunya vaccine accelerated approval in January 2026, 27 months post-grant. Key implications for vaccine regulatory and QA teams managing PMR timelines.
FDA grants interchangeable biosimilar status to Immgolis (golimumab-sldi), raising process validation and GMP expectations for biosimilar manufacturers and CMOs.
FDA's adulterated supplement list now exceeds 40 pain and arthritis products with undisclosed drug ingredients. Key compliance implications for QA and regulatory leads.
FDA's Accelerated Approval Program now includes FDORA Section 3210 reporting. QA and regulatory leads must align postmarket commitments with quarterly surrogate endpoint reports.
FDA approves Genentech's atezolizumab for adjuvant MIBC in ctDNA MRD-positive patients, with Natera's Signatera CDx approved simultaneously as companion diagnostic.
Intellia Therapeutics files rolling BLA for lonvo-z, the first in vivo CRISPR therapy for HAE. Key CMC, LNP manufacturing, and FDA review implications for QA and regulatory leads.
Plus Therapeutics onboards SpectronRx as a second GMP site for REYOBIQ, strengthening radiopharmaceutical supply chain resiliency ahead of pivotal trials.
FDA approves Daiichi Sankyo's Enhertu for two HER2-positive early-stage breast cancer indications. Companion diagnostics approved. ADC manufacturing and pharmacovigilance implications examined.
FDA issued a May 14, 2026 approval letter for GSK Biologicals' BOOSTRIX Tdap vaccine. QA and regulatory teams should review post-market obligations under STN BL 125106.
FDA issues a May 2026 approval letter for GSK's TWINRIX hepatitis A/B vaccine. QA and regulatory teams should review labeling and lot release documentation now.
FDA flags Amazon Basic Care Levonorgestrel 1.5 mg lots delivered past expiration between Jan 2025 and Apr 2026. Key implications for QA and distributor oversight.
Regeneron's Phase 3 fianlimab-cemiplimab trial fails to reach statistical significance on PFS in first-line metastatic melanoma. Key implications for biologics manufacturing and pipeline planning.
Dr. Reddy's becomes first to receive Health Canada approval for generic semaglutide injection. What it means for GLP-1 generics manufacturing and regulatory strategy.
Highlights from the 6th Annual Pharma GMP & Quality Management 2026 in Mumbai, focusing on GMP maturity, digital quality, audit readiness, and predictive quality.
Pharma Quality Excellence Awards 2026 celebrated pharma leaders and organizations in Mumbai for GMP maturity, quality culture, innovation, and excellence.
PSMAddition data show 58% lower PSA progression risk with Pluvicto in mHSPC. Novartis sNDAs filed in US, China, Japan; H2 2026 decisions expected.
Alembic Pharma posts Q4 revenue of Rs. 1,848 crore and enters US branded pharma with Pivya. Key compliance and regulatory implications for Indian manufacturers.
Akums secures EU GMP and UK MHRA certifications and posts Rs. 4,359 crore FY26 revenue. What dual-jurisdiction approval means for Indian CDMO supply chains.
Caplin Steriles secures US FDA ANDA approval for generic foscarnet sodium injection. The US antiviral injectable market for this product is worth ~$15M annually.
Byondis forms a Scientific Advisory Board with ADC pioneers including former ImmunoGen CSO John Lambert to advance its oncology conjugate pipeline.
Gland Pharma posts record Q4 FY26 revenue and near-doubled profit on 38% EBITDA margin. CDMO injectable demand drives results with implications for capacity and quality systems.
Solara Active Pharma's ibuprofen segment recorded negative EBITDA of Rs. 179M in Q4 FY26 despite 61% revenue growth, prompting a strategic review of the API unit.
Japan's MHLW approves Boehringer Ingelheim's nerandomilast for IPF and PPF. The fourth global market clearance raises multi-jurisdiction GMP and regulatory obligations.
Glenmark Pharma enters U.S. injectable generics with Vancomycin, bioequivalent to Fresenius Kabi's RLD. Implications for hospital supply chains and formulary procurement.
Regeneron takes full GMP manufacturing rights for Antibody-Helicon Conjugates in a $2.3B collaboration with Parabilis Medicines, raising new CMC and QA challenges.
FDA accepts Viatris NDA for fast-acting meloxicam in moderate-to-severe acute pain. PDUFA date set for December 27, 2026. Phase 3 data showed reduced opioid use.
Medix Biochemica commits $5M to recombinant antigen capabilities across Finland and Missouri, targeting 60+ validated IVD products by 2030. Q2 2026 evaluation packages available.
Dogwood Therapeutics opens a 12-week Halneuron® CINP extension study to build its end-of-Phase 2 FDA package, with Phase 3 projected to start H1 2027.
FibroBiologics files a USPTO provisional patent for oral fibroblast delivery using multilayer encapsulation and pH-sensitive coatings. Key GMP implications for CMOs and formulation teams.
Capricor's HOPE-3 phase 3 trial meets skeletal and cardiac endpoints for deramiocel in DMD. FDA PDUFA date set August 22, 2026. Key read for regulatory and QA teams.
Inhibrx Biosciences' efdoralprin alfa achieves 3x greater fAAT gains over plasma-derived standard of care in phase 2, with BLA and CMC implications for manufacturers.
Mineralys Therapeutics presents Phase 3 Launch-HTN lorundrostat data at ESH 2026. Key CMC, formulation, and regulatory pathway considerations for CDMOs and QA teams.
Telix Pharmaceuticals closes IPAX-2 enrolment for TLX101-Tx in first-line glioblastoma with no dose-limiting toxicities. Phase 3 IPAX BrIGHT trial actively dosing.
NunaBio secures £6.5M to scale an integrated DNA manufacturing platform for gene therapies and biologics. Key implications for CDMOs and QA teams.
Annora Pharma expands its AltiusHub AI serialization deployment targeting 45% efficiency gains and stronger compliance across US, EU, and emerging export markets.
Strand Life Sciences adds Olink Explore HT proteomics for simultaneous multi-protein analysis, supporting biomarker discovery and drug characterization in Indian biopharma pipelines.
Bayer's NUBEQA combination cut progression or death risk by 71% in Phase II prostate cancer trial. Open-label design limits regulatory weight; Phase III likely needed.
Pfizer promotes Ashish Doshi to Director at IITM Research Park Chennai, reinforcing QA, regulatory compliance, and formulation leadership at a key India site.
SN Bioscience initiates first-patient dosing in a global Phase I trial of SNB-101 for SCLC, with prior cohorts showing 83.3% disease control rate and 6.3-month PFS.
OrganaBio acquires Excellos assets and launches Excellos Labs in San Diego, expanding GMP cell therapy CDMO capacity amid accelerating sector consolidation.
Parexel's ParexelAI platform integrates AI across clinical trials. QA and regulatory leads must assess data integrity, 21 CFR Part 11 compliance, and supply-chain impacts.
Plus Therapeutics partners with Ephemeral Technologies to deploy an AI execution platform unifying CNS oncology datasets across its GBM and leptomeningeal programs.
Anaveon names Eric Zanelli CSO and Jill Jene CBO to lead ANV200's clinical advancement and FDA accelerated approval strategy for autoimmune biologics.
Roche Pharma launches Tecentriq SC in India, the first subcutaneous immunotherapy for lung cancer, cutting IV administration time by 80%. Regulatory and manufacturing implications.
Medix Biochemica commits $5M to expand recombinant antigen capacity, targeting 60+ IVD products by 2030. Key implications for QA and supply chain teams.
Cosette Pharmaceuticals names David Bell Chief Commercial Officer (Brands) to oversee its 21-brand specialty portfolio and drive acquired-asset integration.
Propanc Biopharma selects a European CDMO for GMP manufacture of PRP ahead of a Phase 1b FIH oncology trial. CTA filing targeted for late 2026.
Health Canada approves BioSyent's Thyconvi, Canada's first oral liquid levothyroxine. Key implications for QA directors and regulatory affairs teams on liquid dosage approvals.
Olympia and Wesley Pharmaceuticals promotes Joshua Fritzler from CFO to President, consolidating leadership across two FDA-registered 503B outsourcing facilities in Orlando.
HAB Pharma and Signature Phytochemicals merge into a Rs. 600 crore entity. New sterile and OSD plants due August 2026. Key GMP and validation implications for QA leads.
Zeus Hygia launches Metaberine® in the US and Europe using BioSOLVE Technology. Key regulatory classification and bioavailability data remain undisclosed.
Novo Nordisk presents ESSENCE subgroup analyses at EASL 2026 covering MASH liver safety, menopause, and Japanese patients — with regulatory and supply implications.
NKGen Biotech activates three U.S. sites for its Phase 2 troculeucel trial in Alzheimer's disease, raising GMP batch demand questions for autologous NK cell manufacturing.
Achieve Life Sciences presents ORCA-OL 52-week safety data at ATS 2026, completing the cytisinicline NDA package. No new signals; 2.5% nausea rate reported.